By engaging and empowering researchers using our Translational Care approach, awarding grants using guidance from patients and parents and catalyzing volunteerism among medical and research personnel, we increase the efficiency of research, reducing the average lengths of rare disease identification, research, and drug development cycles.
Our Translational Care model can improve the lives of patients with rare diseases in as little as 18 months to 3 years, creating hope along the way and ultimately impacting how rare conditions are managed.
